Apellis Executive Sells $8,152 in Stock to Cover RSU Taxes; Analysts Update Targets After Q4 Pre-Announcement
Apellis Pharmaceuticals executive Mark Jeffrey DeLong sold 368 shares of company stock on February 11, 2026, for $8,152 to cover tax withholding tied to restricted stock units released the prior day. The transaction leaves DeLong with 114,591 directly held shares. The sale coincides with a corporate pre-announcement of $689 million in fourth-quarte…